Early RA or undiff. arthritis (UA) shows initial hi-dose steroids have significantly better earlier outcomes, but lower doses have fewer early side effects. IMPROVED used high dose GC (60 mg/d tapered to 7.5 mg in 7wks). tREACH used lower dose GC (15 mg/d tapered in 10 wks to https://t.co/TkrGPb6EBZ

JAMA CME review of Immune Thrombotic Thrombocytopenic Purpura (iTTP) - thrombotic microangiopathy w/ hemolytic anemia (MAHA) & thrombocytopenia. iTTP incidence is 2-6 per million. Caused by Abs to ADAMTS13), w/ low ADAMTS13 activity vWF multimers bind platelets https://t.co/bvCexDPBmq

Annals of Internal Medicine has published a CME review of LYME DISEASE. Most Lyme is Dx by onset of the erythema migrans rashes,. Lyme Ab testing is of low sensitivity at onset but more sensitive w/ time & CNS, CV complications. or Mono- or oligoarticular arthritis https://t.co/FMwQgcadik

2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. https://t.co/2NFwTllLZa https://t.co/i5Q5UfE9v3

How Living With Childhood-Onset Lupus Impacts Mental Health Children, teens, and young adults with childhood-onset systemic lupus erythematosus (cSLE) require intense immunosuppressive treatments to prevent organ damage. Recently, the mental health burden for cSLE patients has https://t.co/JXkdYiAO9o

Emulation Trials in SLE: Real or Fake Dr. Janet Pope, Ontario, Canada, discusses emulation trials in systemic lupus erythematosus. https://t.co/wVmMfLVAuQ https://t.co/V4VGVncSE9

2024 ACR Lupus Nephritis Guidelines: The Controversies Drs. Maria Dall’Era & Michelle Petri discuss the sticking points in the latest lupus nephritis recommendations. 🗣️ Insightful, honest, and essential for your practice. 📍Full update on RheumNow: https://t.co/KPjyCrMTBr https://t.co/VoOslSqs99

IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/sbXW6vNX5y

Moving Targets in Lupus and Lupus Trials In the 1990s, developing lupus treatments became a priority, but success was elusive for 20 years. Belimumab was approved by showing only small differences from placebo in trials with 867 patients globally. Its efficacy was confirmed by https://t.co/TekxzTJjwC

Steroids in Lupus Nephritis: No Free Lunch https://t.co/yPQuZcnRLH https://t.co/V8GZoslSqV

NEW for #LUPUS2025—@ern_reconnet–SLICC–@SLEuroSociety expert consensus on the therapeutic management of rare systemic #lupus erythematosus manifestations https://t.co/XwAHpsho57 Free to read with registration on https://t.co/28wkm5ab69 (also free) @Lupusreference #SLE https://t.co/73K0DKTHye

🔺CTD-ILD radiological signs to look out for 👀 #CTD #ILD #UIP #NSIP #Fibrosis #scleroderma #systemicsclerosis #Sjogrens #Lupus By @IlliasulK https://t.co/hHupTz0bCy